What is NBIX's current stock price?

NBIX is currently trading at $128.38 with a daily change of -0.19%. Visit StocksRunner for live updates.

What are NBIX stock's key strengths?

NBIX current strengths include: Outperform the market, Earnings are forecast to grow, Upgraded on attractively valued. These are updated in real time by the StocksRunner IQ algorithm.

What are the risks associated with NBIX stock?

Current risk factors for NBIX include: Low. Risk levels are assessed by StocksRunner based on volatility, sector strength, volume, and investor confidence.

What is NBIX's current StocksRunner IQ Score?

NBIX current StocksRunner IQ Score is: Hold. This score reflects aggregated earnings data, news sentiment, analyst ratings, and market momentum as of the latest update.

What factors influence NBIX's StocksRunner IQ Score?

NBIX StocksRunner IQ Score is a composite Credibility Score that weighs: quarterly earnings results vs. analyst expectations, breaking news sentiment and headline credibility, Wall Street analyst price target consensus, trading volume and price momentum, and sector-level risk indicators. All factors are aggregated in real time.

<

Market Overview Trending Stocks Stock Screener Trade Insights

Top Rated Stocks Most Active Stocks Top Potential Stocks Top Momentum Stocks Leaderboard

About Us Log In Sign Up Plans & Pricing Contact Us Terms of Use Privacy Policy

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist

NBIX Stock Analysis & IQ Rating | Neurocrine Biosciences

Q: Should I buy NBIX stock right now?

StocksRunner does not provide personalized investment advice. Our IQ Credibility Score for NBIX aggregates analyst sentiment, earnings performance, and news momentum to help you make an informed decision. The current IQ signal is: Hold. Always consider your own risk tolerance and consult a financial advisor before investing.

Q: What does a Strong Buy rating mean for NBIX?

A Strong Buy rating on StocksRunner indicates that the aggregated IQ score — drawing from earnings beats, analyst upgrades, and positive news sentiment — reflects high confidence in NBIX near-term growth potential. It is the strongest signal in the StocksRunner IQ rating scale.

NBIX

Neurocrine Biosciences

$128.38

-$0.25 | -0.19%

Set Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Headlines

52W High

$160.18

MKT CAP

$12.88B

52W Low

$84.23

VOL

$764.97K

P/E Ratio

27.49

AVG VOL

$1.26M

RSI

40.67

TREND

Downtrend

NBIX Stock IQ

Login to see Neurocrine Biosciences (NBIX) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

NBIX Target Price

Login to display

Strengths

NBIX Rewards

Upgraded on attractively valued

NBIX Rewards

Earnings are forecast to grow

NBIX Rewards

Outperform the market

NBIX Price Performance

$134.51 (-4.56%)

$143.53 (-10.56%)

$140.27 (-8.48%)

$110.87 (+15.79%)

1year

6month

3month

1month

NBIX Analysts Opinion

Overall standing based on market and analyst consensus. menu Hover over the category for more information

NBIX Analysts opinion is negative and it remained unchanged from the past 3 months

NBIX Street Sentiment

Analysts perspectives on the stock desirability, trend direction and growth potential

63%

Consensus Rating

100%

Buy
Opinion

33%

Trend
Score

0%

Potential
Score

NBIX Street Sentiment is bullish but have mixed views on the near-term outlook

NBIX Risk Level

NBIX has Low risk level

Low

LOW

HIGH

NBIX Performance Sentiment

Sentiments overview associated with events and the stock performance

63%

Positive

12 out of 19
events present

37%

Negative

7 out of 19
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Key Price Levels

Average key support and resistance price levels

Support Price

$123.10

Resistance Price

$154.06

Current Price Range

$128.63

$123.10

$154.06

Show methods +

Analyst Consensus

Recent Upgrades and Downgrades

92%

Consensus Rating

STRONG BUY

12

Buy

1

Hold

0

Sell

Date

Action

Rating

Firm

Dec 18, 2025

Reiterate

Buy

HC Wainwright & Co.

Dec 13, 2025

Reiterate

Neutral

Mizuho

Dec 12, 2025

Reiterate

Buy

Stifel

Dec 09, 2025

Reiterate

Outperform

RBC

Dec 06, 2025

Reiterate

Buy

TD Cowen

NBIX Latest Analysis +

Analysts Stay ish As Neurocrine Shares Tumble On Disappointing Ingrezza Guidance. ) on Wednesday reported fourth-quarter adjusted earnings of $1.88 per share .Sales reached $805.5 million beating the consensus of $792.47 million.Fourth-quarter net product sales were $798.3 million up 29% year over year.Ingrezza (drug for involuntary movements) fourth-quarter and full-year 2025 net product sales were $657.5 million and $2.51 billion reflecting 7% and 9% growth year-over-year respectively.Results

Thu Feb 12, 2026

$123.10 | -10.43%

Activity

Momentum

Potential

Neurocrine Biosciences Inc. (NASDAQ:NBIX) Q4 2025 Earnings Call Transcript. Neurocrine Biosciences Inc. (NASDAQ:NBIX) Q4 2025 Earnings Call Transcript February 11 2026 Neurocrine Biosciences Inc. misses on earnings expectations. Reported EPS is $1.5 EPS expectations were $2.25. Operator: Hello and welcome everyone joining today’.s Neurocrine Biosciences Fourth Quarter and Fiscal Year 2025 Earnings Call. [Operator Instructions] Please note this call is being recorded. [Operator Instructions]

Thu Feb 12, 2026

$123.10 | -10.43%

Earnings

Neurocrine Bio. stock price target lowered to $192 at H.C. Wainwright.

Thu Feb 12, 2026

$123.10 | -10.43%

Potential

Neurocrine Biosciences Inc (NBIX) Q4 2025 Earnings Call Highlights: Strong Sales Growth and ... This article first appeared on GuruFocus.-Total Product Sales: Over $2.8 billion representing 22% year-over-year growth.-Ingrezza Revenue: Just over $2.5 billion up 9% year-over-year.-Chronicity Net Product Sales: Exceeded $300 million in the first full commercial year.-Cash Position:

Thu Feb 12, 2026

$123.10 | -10.43%

Activity

Earnings

Neurocrine expects INGREZZA sales to reach up to $2.8B in 2026 amid CRENESSITY launch momentum.

Wed Feb 11, 2026

$137.44 | -0.15%

Activity

Neurocrine Biosciences Non-GAAP EPS of $1.88 misses by $0.42 revenue of $805.5M beats by $16.2M.

Wed Feb 11, 2026

$137.44 | -0.15%

Earnings

Preview: Neurocrine Biosciencess Earnings. Neurocrine Biosciences (NASDAQ:) is gearing up to announce its quarterly earnings on Wednesday 2026-02-11. Here'.s a quick overview of what investors should know before the release.Analysts are estimating that Neurocrine Biosciences will report an Neurocrine Biosciences s will hope to hear the company announce they'.ve not only beaten that estimate but also to provide positive guidance or forecasted growth for the next quarter.New investors shou

Tue Feb 10, 2026

$137.65 | -1.37%

Activity

Earnings

Momentum

Exploring Analyst Estimates for Neurocrine (NBIX) Q4 Earnings Beyond Revenue and EPS. Get a deeper insight into the potential performance of Neurocrine (NBIX) for the quarter ended December 2025 by going beyond Wall Streets top-and-bottom-line estimates and examining the estimates for some of its key metrics.

Fri Feb 6, 2026

$141.20 | +2.37%

Earnings

Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth. Neurocrine (NBIX) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Wed Feb 4, 2026

$137.86 | -0.81%

Earnings

FAQ About NBIX Stock Insights

What is NBIX current stock price?

What are NBIX stock strengths?

What is NBIX Risk Level?

What is NBIX market cap and volume?

What is NBIX current Stock IQ?

Should I buy NBIX stock right now?

Is NBIX a Strong Buy right now?

What does a 'Strong Buy' rating mean for NBIX?

What does a 'Strong Sell' rating mean for NBIX?

What factors influence NBIX's Stock IQ?

Explore our NBIX Stock insights

In-Depth Market Analysis and Trends
Expert Insights on Market Dynamics
Tailored NBIX Stock Strategies
Effective Risk Management

FIND US ON

Receive our NBIX Daily Alerts

Join our subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

NBIX

Neurocrine Biosciences

Set Alerts

Current Price

$128.38

-$0.25 | -0.19%

52W High

$160.18

MKT CAP

$12.88B

52W Low

$84.23

VOL

$764.97K

P/E Ratio

27.49

AVG VOL

$1.26M

RSI

40.67

TREND

Downtrend

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

NBIX Price Performance

$134.51 (-4.56%)

$143.53 (-10.56%)

$140.27 (-8.48%)

$110.87 (+15.79%)

1year

6month

3month

1month

NBIX Analysts Opinion

Overall standing per market and analyst expectations. menu Hover over the category for more information

NBIX Analysts opinion is negative and it remained unchanged from the past 3 months

NBIX Street Sentiment

Analysts perspectives on the stock desirability, trend direction and growth potential

63%

Consensus Rating

100%

Buy
Opinion

33%

Trend
Score

0%

Potential
Score

NBIX Street Sentiment is bullish but have mixed views on the near-term outlook

NBIX Risk Level

NBIX has Low risk level

Low

LOW

HIGH

NBIX Performance Sentiment

Sentiments overview associated with events and the stock performance.

63%

Positive

12 out of 19
events present

37%

Negative

7 out of 19
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Key Price Levels

Average key support and resistance price levels

Support Price

$123.10

Resistance Price

$154.06

Current Price Range

$128.63

$123.10

$154.06

Show methods +

Latest Analyst Actions

Overall Wall Street Rating

92%

Consensus Rating

STRONG BUY

12

Buy

1

Hold

0

Sell

Date

Action

Rating

Firm

Dec 18, 2025

Reiterate

Buy

HC Wainwright & Co.

Dec 13, 2025

Reiterate

Neutral

Mizuho

Dec 12, 2025

Reiterate

Buy

Stifel

Dec 09, 2025

Reiterate

Outperform

RBC

Dec 06, 2025

Reiterate

Buy

TD Cowen

NBIX Stock IQ

Login to unlock Neurocrine Biosciences (NBIX) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

Target Price

Login to display

Stock Insights

Strengths

NBIX Rewards

Upgraded on attractively valued

NBIX Rewards

Earnings are forecast to grow

NBIX Rewards

Outperform the market

NBIX Latest Analysis

Analysts Stay ish As Neurocrine Shares Tumble On Disappointing Ingrezza Guidance. ) on Wednesday reported fourth-quarter adjusted earnings of $1.88 per share .Sales reached $805.5 million beating the consensus of $792.47 million.Fourth-quarter net product sales were $798.3 million up 29% year over year.Ingrezza (drug for involuntary movements) fourth-quarter and full-year 2025 net product sales were $657.5 million and $2.51 billion reflecting 7% and 9% growth year-over-year respectively.Results

Thu Feb 12, 2026

$123.10 | -10.43%

Activity

Momentum

Potential

Neurocrine Biosciences Inc. (NASDAQ:NBIX) Q4 2025 Earnings Call Transcript. Neurocrine Biosciences Inc. (NASDAQ:NBIX) Q4 2025 Earnings Call Transcript February 11 2026 Neurocrine Biosciences Inc. misses on earnings expectations. Reported EPS is $1.5 EPS expectations were $2.25. Operator: Hello and welcome everyone joining today’.s Neurocrine Biosciences Fourth Quarter and Fiscal Year 2025 Earnings Call. [Operator Instructions] Please note this call is being recorded. [Operator Instructions]

Thu Feb 12, 2026

$123.10 | -10.43%

Earnings

Neurocrine Bio. stock price target lowered to $192 at H.C. Wainwright.

Thu Feb 12, 2026

$123.10 | -10.43%

Potential

Neurocrine Biosciences Inc (NBIX) Q4 2025 Earnings Call Highlights: Strong Sales Growth and ... This article first appeared on GuruFocus.-Total Product Sales: Over $2.8 billion representing 22% year-over-year growth.-Ingrezza Revenue: Just over $2.5 billion up 9% year-over-year.-Chronicity Net Product Sales: Exceeded $300 million in the first full commercial year.-Cash Position:

Thu Feb 12, 2026

$123.10 | -10.43%

Activity

Earnings

Neurocrine expects INGREZZA sales to reach up to $2.8B in 2026 amid CRENESSITY launch momentum.

Wed Feb 11, 2026

$137.44 | -0.15%

Activity

Neurocrine Biosciences Non-GAAP EPS of $1.88 misses by $0.42 revenue of $805.5M beats by $16.2M.

Wed Feb 11, 2026

$137.44 | -0.15%

Earnings

Preview: Neurocrine Biosciencess Earnings. Neurocrine Biosciences (NASDAQ:) is gearing up to announce its quarterly earnings on Wednesday 2026-02-11. Here'.s a quick overview of what investors should know before the release.Analysts are estimating that Neurocrine Biosciences will report an Neurocrine Biosciences s will hope to hear the company announce they'.ve not only beaten that estimate but also to provide positive guidance or forecasted growth for the next quarter.New investors shou

Tue Feb 10, 2026

$137.65 | -1.37%

Activity

Earnings

Momentum

Discover NBIX Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends and the future potential of NBIX. We're here to help you make informed investment decisions today.

FIND US ON

Receive our NBIX Daily Alerts

Unlock the knowledge that 5,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

NBIX Stock trends

NBIX Stock performance

NBIX Stock analysis

NBIX investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner Insights

Financial Reports

Disclaimer: The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing NBIX

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence and cutting-edge intelligence.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing NBIX

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence and cutting-edge intelligence.

NBIX Stock Analysis & IQ Rating | Neurocrine Biosciences

NBIX Stock IQ

NBIX Target Price

NBIX Analysts Opinion

NBIX Street Sentiment

NBIX Risk Level

NBIX Performance Sentiment

Key Price Levels

Analyst Consensus

Explore our NBIX Stock insights

Receive our NBIX Daily Alerts

NBIX Street Sentiment

NBIX Risk Level

Key Price Levels

Latest Analyst Actions

Discover NBIX Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends and the future potential of NBIX. We're here to help you make informed investment decisions today.

Receive our NBIX Daily Alerts

NBIX Alerts